bioAffinity Technologies
BIAF
12 hedge funds and large institutions have $928K invested in bioAffinity Technologies in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 3 closing their positions.
903% more capital invested
Capital invested by funds: $92.5K → $928K (+$836K)
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
50% more funds holding
Funds holding: 8 → 12 (+4)
3.64% more ownership
Funds ownership: 1.74% → 5.38% (+3.6%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JSSH
J. Safra Sarasin Holding
|
+$68.8K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$39.4K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$28.9K |
| 4 |
State Street
Boston,
Massachusetts
|
+$23.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$14.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$13.7K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$13.1K |
| 3 |
Citigroup
New York
|
-$12.4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.96K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$45 |
BIAF Hedge Fund Activity: Q1 2026 in Review
12 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q1 2026, worth a combined $928K — up 903% from $92.5K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BIAF positions and 3 closed out — a net gain of 4 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was J. Safra Sarasin Holding, opening a new position worth an estimated $68.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $13.7K sold.
- 12 institutional investors held bioAffinity Technologies (BIAF) as of Q1 2026, up from 8 in Q4 2025.
- Funds reported $928K of bioAffinity Technologies stock for Q1 2026, up 903% quarter-over-quarter.
- 7 funds opened new bioAffinity Technologies positions in Q1 2026 and 3 closed out, a net change of +4 holders.
- The largest bioAffinity Technologies buyer in Q1 2026 was J. Safra Sarasin Holding, an estimated $68.8K added.
- The largest bioAffinity Technologies seller in Q1 2026 was Citadel Advisors, an estimated $13.7K sold.
Based on aggregated 13F filings for Q1 2026.